Shoulder Innovations has developed and commercialized various components for the InSet Glenoid, Humeral Short Stem, Reverse and Stemless implants.

The company declined in the mid-teens during 2022 as it exits markets, fills portfolio gaps and modernizes its operations.

The company grew 23% in 2022, its first year as a publicly traded company. New products and sales force expansion drove the growth.

The company grew more than 44% in 2022 through its sole focus on spine surgery. ATEC expects to grow another 25% in 2023.

The company’s product revenue declined in the low single digits in 2022 as it transforms its business model and contends with supply issues.

The company grew 18% in 2022, driven by accelerating demand momentum in its core SI-fusion business and increased surgeon engagement.

Our chart of the month shows the projected top 10 largest players in spine after recent M&A deals in the market segment.

The company’s MACI sales grew more than 18% for FY22 and greatly accelerated its path toward a new arthroscopic delivery method.

Enovis reported 4Q22 orthopedic sales of $162.5 million, +10.4% compared to 4Q21. Including contributions from acquisitions, the company generated $599.4…

The company’s reported orthopedic sales grew by low-single digits during the third quarter of its 2023 fiscal year.